Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
about
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaHepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention StrategiesAssociation of Lymphomagenesis and the Reactivation of Hepatitis B Virus in Non-Hodgkin LymphomaAntiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)Management of patients with hepatitis B who require immunosuppressive therapyOutcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factorsCancer and liver cirrhosis: implications on prognosis and managementPrevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapyHepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-ScreenedTreatment of rheumatic diseases and hepatitis B virus coinfectionHepatitis C virus screening in patients with cancer receiving chemotherapy.Reporting of serious adverse events during cancer clinical trials to the institutional review board: an evaluation by the research on adverse drug events and reports (RADAR) project.Hepatitis B virus management to prevent reactivation after chemotherapy: a review.The hepatitis B virus x protein inhibits thymine DNA glycosylase initiated base excision repair2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.Case report: passive transfer of hepatitis B antibodies from intravenous immunoglobulin.B Lymphocytes Are Required during the Early Priming of CD4+ T Cells for Clearance of Pneumocystis Infection in Mice.Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma.Longitudinal risk of herpes zoster in patients with non-Hodgkin lymphoma receiving chemotherapy: A nationwide population-based study.Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy.Risk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma Patients: A Large Cohort Retrospective Study.Factors associated with hepatic dysfunction in hepatitis B-positive patients with postgastrectomy adenocarcinoma.Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable.Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy.Fatal Hepatocellular Carcinoma in a Patient with Occult Hepatitis B Virus Infection following the Administration of R-CHOP for Diffuse Large B-Cell LymphomaHepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver DiseasesVeterans health administration hepatitis B testing and treatment with anti-CD20 antibody administrationResults from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project.Screening and evaluation of chronic and occult Hepatitis B in chemo - radiotherapy patients with cancer.Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy.Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threatHepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab.Improving testing for hepatitis B before treatment with rituximab.Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.The management of chronic hepatitis B in Asian Americans.
P2860
Q24203027-9FE0AEF4-D618-498E-87C1-F82DCBA52554Q26746486-06A8A33F-DAA4-46AC-BD75-4DB3820DCD1AQ26782217-BD3CA52F-9C40-4EFA-886B-4840E93D09D9Q26801716-54E22F44-37C1-46F3-AF00-473C607DAF4AQ26853490-88187F33-1866-493E-A751-9389007C912FQ27020938-5655FB47-585F-4B02-94E6-9B35BD08CCA8Q28068579-9C89B664-600B-474C-8EA8-70D53B0EE4CCQ28070090-8EC86A18-51B7-4330-88DC-7109DAA2D68BQ28076703-14B8AA39-78C1-40AD-8058-29882FF47E15Q28084305-D3976DFC-BE61-4EF2-8394-60667F9E5F30Q33600085-3A8B5BC7-55F1-42DB-8FF8-EDE223CD29D8Q34370603-65BFFF9C-2319-4E65-86B7-E5A4334A462FQ34397738-5D9A5B82-DD4D-4BB1-AE68-1E0BFF849C98Q34473782-76956536-1B95-491D-8C69-FD6FAC5561C3Q34500921-C3FCA630-A093-4C35-84F2-8D36C7BC327EQ35037621-72E28827-F234-4ACE-8896-8B8A027A9A29Q35055076-2B158958-D30C-4931-8384-C9E835F6891CQ35095916-88DD6ADB-D5C9-49CE-A230-3480398ED504Q35100218-518792BE-CF31-4BDF-B8C0-EF0F5FDA61E9Q35816029-C669C166-4A4E-496E-BFE6-2A83F2639064Q35992515-C6988FA3-73CF-4178-96CD-72A2DF3A1722Q36099232-FACEC7A2-415E-4DE4-8517-7DE64831A8B6Q36121117-778E2F0A-0648-416E-A73A-A168E84CEE1FQ36154994-294CCEC4-F784-4000-9CAB-7B1B8855C7EBQ36195013-9E5ADB6B-8D08-49FD-94EA-4FA81B5BB192Q36225933-574DBCD5-D26A-486D-9A32-1B49967A52DBQ36311839-6BBDC3A6-569B-4162-9E16-2B82175379E8Q36364001-930D8842-31BC-4592-BEF9-48F9B3F611DFQ36522482-E5C94132-0A17-415B-84E6-067663964638Q36803202-BF6FDACD-38F4-4F64-A990-A405853B9B22Q36909250-DC74AAB7-ECEC-4B63-A143-F65067CF6548Q36920523-29F0D69A-8740-46AD-9812-61275BF8E39BQ36934702-D6433E3A-4623-4C92-8B9C-A7FAEC7010A5Q36958944-7B1EA6E2-05B8-4053-84CA-1BD9E2DA6FA2Q37031689-E6AE72B6-67D1-4349-915A-30C22C322D2BQ37049118-50B00CF4-9094-4C84-B724-9BFF3FF6CECDQ37082428-FED2EC95-AB02-437A-B53C-D1643C96BDCAQ37229995-0FD604E8-B4B8-4D90-BEC8-71D71D17EB9BQ37928299-A184A1F0-D65E-4920-8567-974760DF879DQ37936321-A52D1DBA-9AB4-4F4C-9E27-86C453E5AA6D
P2860
Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Rituximab-associated hepatitis ...... mination of FDA safety reports
@ast
Rituximab-associated hepatitis ...... mination of FDA safety reports
@en
Rituximab-associated hepatitis B virus
@nl
type
label
Rituximab-associated hepatitis ...... mination of FDA safety reports
@ast
Rituximab-associated hepatitis ...... mination of FDA safety reports
@en
Rituximab-associated hepatitis B virus
@nl
prefLabel
Rituximab-associated hepatitis ...... mination of FDA safety reports
@ast
Rituximab-associated hepatitis ...... mination of FDA safety reports
@en
Rituximab-associated hepatitis B virus
@nl
P2093
P2860
P356
P1433
P1476
Rituximab-associated hepatitis ...... mination of FDA safety reports
@en
P2093
B D Jovanovic
B-C C Chiu
D W Raisch
S M Belknap
P2860
P304
P356
10.1093/ANNONC/MDQ583
P577
2010-11-29T00:00:00Z